Fourteen-day vonoprazan-amoxicillin dual therapy versus 14-day bismuth-based quadruple therapy for treatment: a randomized clinical trial
Background: Potassium-competitive acid blockers (P-CABs) have shown potential in Helicobacter pylori ( H. pylori ) eradication, but the efficacy of dual therapy with P-CABs and amoxicillin remains underexplored. Objectives: This study evaluated the efficacy, safety, and compliance of a 14-day vonopr...
Saved in:
| Main Authors: | Jin-Yan Zhang, Jin-Hai Chen, Yu-Lin Huang, Ji Li, Dong Xu, Zhong Xu, Xiao-Yi Lei |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-07-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/17562848251354868 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ten-day vonoprazan–amoxicillin dual therapy versus 14-day esomeprazole–amoxicillin dual therapy for first-line eradication: a prospective multicenter randomized controlled trial
by: Ben-Gang Zhou, et al.
Published: (2024-12-01) -
Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis
by: Xiao Li, et al.
Published: (2025-03-01) -
Vonoprazan–minocycline dual therapy as a first-line treatment of infection compared with empirical bismuth-containing quadruple therapy
by: Meng Li, et al.
Published: (2025-08-01) -
Efficacy and Safety of 10‐Day Versus 14‐Day Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis
by: Najam Gohar, et al.
Published: (2025-03-01) -
Efficacy and cost-effectiveness analysis of 10-day versus 14-day eradication of Helicobacter pylori infection with vonoprazan amoxicillin: a prospective, multicenter, randomized controlled trial
by: Yunfan Dong, et al.
Published: (2025-03-01)